Importantly, three recent reports showed that CFHR1, CFHR2, and CFHR5 deregulate complement by competing with FH for binding to C3b, and thus they may rather enhance complement activation in human renal diseases (11–13). This evidence concerns the gene C3 and kidney disorder.